c-MET (Y1235D)

MET · Variant type: point · HGVS: p.Y1235D

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Cabozantinib	99.7%	0.3%	92.73
2	Capmatinib	93.4%	6.6%	99.75
3	Crizotinib	92.6%	7.4%	91.39
4	Tepotinib	91.1%	8.9%	99.75
5	Gilteritinib	87.4%	12.6%	88.97
6	Deucravacitinib	86.3%	13.7%	98.99
7	Pacritinib	67.1%	32.9%	88.64
8	Tivozanib	54.7%	45.3%	92.42
9	Canertinib	54.6%	45.4%	96.49
10	Afatinib	53.1%	46.9%	98.50
11	Defactinib	48.4%	51.6%	92.68
12	Dacomitinib	45.8%	54.2%	97.99
13	Pazopanib	44.9%	55.1%	97.49
14	Axitinib	43.1%	56.9%	93.23
15	Gefitinib	42.0%	58.0%	99.25
16	Abemaciclib	41.5%	58.5%	91.48
17	Dabrafenib	35.8%	64.2%	94.74
18	Bosutinib	33.9%	66.1%	87.22
19	Ponatinib	33.7%	66.3%	78.23
20	Nintedanib	30.4%	69.6%	90.23
21	Sirolimus	28.4%	71.6%	100.00
22	Lenvatinib	26.6%	73.4%	97.74
23	Nilotinib	25.2%	74.8%	96.49
24	Neratinib	23.9%	76.1%	93.18
25	Dasatinib	22.6%	77.4%	87.97

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Cabozantinib	99.7%	—	—
Capmatinib	93.4%	—	—
Crizotinib	92.6%	—	—
Tepotinib	91.1%	—	—
Gilteritinib	87.4%	—	—
Deucravacitinib	86.3%	—	—
Pacritinib	67.1%	—	—
Tivozanib	54.7%	—	—
Canertinib	54.6%	—	—
Afatinib	53.1%	—	—
Defactinib	48.4%	—	—
Dacomitinib	45.8%	—	—
Pazopanib	44.9%	—	—
Axitinib	43.1%	—	—
Gefitinib	42.0%	—	—
Abemaciclib	41.5%	—	—
Dabrafenib	35.8%	—	—
Bosutinib	33.9%	—	—
Ponatinib	33.7%	—	—
Nintedanib	30.4%	—	—
Sirolimus	28.4%	—	—
Lenvatinib	26.6%	—	—
Nilotinib	25.2%	—	—
Neratinib	23.9%	—	—
Dasatinib	22.6%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.3ms